MAGE-A3 mRNA expression was available in the TCGA and the Cancer Cell Line Encyclopedia (CCLE) for 106 leiomyosarcoma tumors (LMS), 76 undifferentiated pleomorphic sarcoma/myxofibrosarcomas (UPS/MFS), 58 dedifferentiated liposarcomas (DDLPS), 10 synovial sarcomas, 10 malignant peripheral nerve sheath tumors (MPNST), and 46 various sarcoma cell lines. This evidence concerns the gene MAGEA3 and synovial sarcoma.